

CERTIFICATE OF ANALYSIS

NAD+ - 1000 mg


Oxidised beta-nicotinamide adenine dinucleotide - non-peptide coenzyme

Material	NAD+	Client	novumpeptides.com	Received	2026-04-15 at 2-8 C
Batch / lot	NAD-05-9NW	Label claim	1000 mg	Analysed	2026-04-16 to 2026-04-17

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	Conforms	Matches beta-NAD+ reference	MA-MS-022 / LC-MS	Conforms
Beta-NAD+ assay (area %)	99.38%	>= 99.00%	MA-HPLC-041 / UV 260	Pass
NADH	0.14%	<= 0.30%	MA-HPLC-041 / UV 340	Pass
ADP-ribose	0.18%	<= 0.30%	MA-HPLC-041 / UV 260	Pass
NAD+ per vial (n=2)	1002.00 mg	900.00-1100.00 mg	MA-ASSAY-041 / HPLC-UV	Pass
Water content	4.38%	<= 8.00%	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	197 ppm	<= 410 ppm	MA-GC-006 / HS-GC-FID	Pass
pH, 1% solution	3.2	2.5-4.0	MA-PH-002 / potentiometry	Pass

RP-UHPLC processed trace, UV detection



Record UKFZ9NW-NAD-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

ADP-ribose	0.18%
NADH	0.14%
NMN	0.10%
ADP	0.07%
nicotinamide	0.06%
unresolved peaks	0.07%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Beta-NAD+ identity and chromatographic assay met the stated criteria. Mean content was 1002.00 mg/vial and beta-NAD+ area purity was 99.38%.

NAD+ is a nucleotide coenzyme, not a peptide; identity and purity were therefore assessed by LC-MS and ion-pair HPLC with UV detection.

Analytical review

Ines Abadi I. Abadi

Quality review

Marcus Oyelaran

Approval date: 2026-04-18 M. Oyelaran

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.